本帖最后由 老马 于 2012-1-13 21:20 编辑
* j" u; n% l; ^. G" Z8 a
2 N- d- t# P& A2 w# |' m% Z5 P. ]爱必妥和阿瓦斯丁的比较
/ ]) y% {- r" i) T/ J, T
0 X# D; Z* I! p! D" {7 N
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
& T9 C" n) ]; F/ e0 V) K
7 B4 u; e: ` I/ ]- w7 _) \& F
; ]- t& ]* W9 f7 Bhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/0 ^0 Y$ B: b/ U- X; K+ T
==================================================
# l- G# M1 o' A. UOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
, t4 E8 t" b0 @3 M+ |9 N' q1 ~! l+ _Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
1 r; [2 U7 m/ ]4 N2 LResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
; k6 F1 }. {, c$ b- B
|